Ir a las transacciones
Salud | TMT

Bayer AG has entered into a takeover agreement with Cara Care

December 2024 — Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Cara Care is a digital digestive health solution from Germany that combines both mental and nutritional therapy options. Its MDR Class I-approved treatment for irritable bowel syndrome (IBS) is fully reimbursed by all German statutory health insurance (SHI) and DiGA-certified providers. DiGA refers to digital health applications that are approved for use in Germany and are eligible for reimbursement under the country’s SHI system. The company is a pioneer in the field and is driving growth in an underserved sector. Cara Care has built a product pipeline that addresses not only IBS but also heartburn, dyspepsia and inflammatory bowel disease (IBD).

Bayer AG is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863 and headquartered in Leverkusen, Germany, Bayer is known for its innovation-driven approach to improving quality of life. The company operates across three main divisions: pharmaceuticals, consumer health and crop science, delivering products and solutions that address some of the world’s most pressing challenges, particularly in health and food security.

Our role in the transaction

Oaklins’ team in Germany provided comprehensive advisory services to the insolvency administrator and Cara Care in this transaction.

Partes

Contáctese con el equipo de la transacción

Jan P. Hatje

Socio Director
Hamburgo, Alemania
Oaklins Germany

Kevin Kambach

Asociado Senior
Hamburgo, Alemania
Oaklins Germany

Transacciones relacionadas

Freeway Fleet Systems has been acquired by Movement Software
TMT

Freeway Fleet Systems has been acquired by Movement Software

Freeway Fleet Systems has been acquired by Movement Software, strengthening its position as a leading provider of fleet management and maintenance software while expanding the group’s presence into the UK market. As a strategic consolidator focused on transportation and mobility software, Movement Software will benefit from immediate product and customer synergies, with Freeway providing a strong platform for further geographic expansion across key fleet end markets.

Aprenda más
Comtax has been acquired by Ryan
Private Equity | Servicios de Soporte Comercial | TMT

Comtax has been acquired by Ryan

Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.

Aprenda más
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Salud

Katalyst Diagnostics has been acquired by Cruinn Diagnostics

Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.

Aprenda más